Trending...
- Pennsylvania: Gov. Wolf Recognizes Grocery Store Workers, Now Vaccine Eligible, for Heroic Work
- Children's Hospital of Philadelphia's Dr. N. Scott Adzick Receives Clinical and Translational Science Distinguished Investigator Award for Bringing Fetal Surgery from the Lab to the Clinic
- TVS Main Street Network Returns Petticoat Junction to Tuesday Nights on WatchYour.TV Platform
BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith reminds investors of the upcoming April 13, 2021 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased bluebird bio, Inc. ("bluebird" or the "Company") (NASDAQ: BLUE) securities between May 11, 2020 and November 4, 2020, inclusive (the "Class Period").
Investors suffering losses on their bluebird investments are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal rights in this class action at 888-638-4847 or by email to howardsmith@howardsmithlaw.com.
In May 2020, in the midst of the COVID-19 pandemic, bluebird announced that the Company expected to submit a U.S. Biologics Licensing Application ("BLA") to the U.S. Food and Drug Administration ("FDA") for LentiGlobin for sickle cell disease in the second half of 2021.
More on The PennZone
On November 4, 2020, post-market, bluebird disclosed that it would delay its BLA submission to late 2022 due to "feedback" from the FDA that requires the Company to provide additional data "to demonstrate drug product comparability" for LentiGlobin for sickle cell disease, as well as "COVID-19 related shifts and contract manufacturing organization COVID-19 impacts."
On this news, bluebird's stock price fell $9.72 per share, or 16.6%, to close at $48.83 per share on November 5, 2020.
The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company's business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) data supporting bluebird's BLA submission for LentiGlobin for SCD was insufficient to demonstrate drug product comparability; (2) Defendants downplayed the foreseeable impact of disruptions related to the COVID-19 pandemic on the Company's BLA submission schedule for LentiGlobin for SCD, particularly with respect to manufacturing; (3) as a result of all the foregoing, it was foreseeable that the Company would not submit the BLA for LentiGlobin for SCD in the second half of 2021; and (4) as a result, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times.
More on The PennZone
If you purchased or otherwise acquired bluebird securities during the Class Period, you may move the Court no later than April 13, 2021 to ask the Court to appoint you as lead plaintiff if you meet certain legal requirements. To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action. If you wish to learn more about this class action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020, by telephone at (215) 638-4847, toll-free at (888) 638-4847, or by email to howardsmith@howardsmithlaw.com, or visit our website at www.howardsmithlaw.com.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Investors suffering losses on their bluebird investments are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal rights in this class action at 888-638-4847 or by email to howardsmith@howardsmithlaw.com.
In May 2020, in the midst of the COVID-19 pandemic, bluebird announced that the Company expected to submit a U.S. Biologics Licensing Application ("BLA") to the U.S. Food and Drug Administration ("FDA") for LentiGlobin for sickle cell disease in the second half of 2021.
More on The PennZone
- INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Ebang International Holdings, Inc. (EBON) Investors
- Fifty States of Vodka is Now Available in Every Total Wine In Florida
- TVS Classic Sports Network Adds Iconic College Football Classics to Program Schedule on WatchYour.TV
- BOLD-100 MoA Research to Be Presented at the AACR Annual Meeting
- Mensa Foundation Celebrates 50 Years of Unleashing Intelligence
On November 4, 2020, post-market, bluebird disclosed that it would delay its BLA submission to late 2022 due to "feedback" from the FDA that requires the Company to provide additional data "to demonstrate drug product comparability" for LentiGlobin for sickle cell disease, as well as "COVID-19 related shifts and contract manufacturing organization COVID-19 impacts."
On this news, bluebird's stock price fell $9.72 per share, or 16.6%, to close at $48.83 per share on November 5, 2020.
The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company's business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) data supporting bluebird's BLA submission for LentiGlobin for SCD was insufficient to demonstrate drug product comparability; (2) Defendants downplayed the foreseeable impact of disruptions related to the COVID-19 pandemic on the Company's BLA submission schedule for LentiGlobin for SCD, particularly with respect to manufacturing; (3) as a result of all the foregoing, it was foreseeable that the Company would not submit the BLA for LentiGlobin for SCD in the second half of 2021; and (4) as a result, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times.
More on The PennZone
- INVESTOR ALERT: Law Offices of Howard G. Smith Continues Investigation of Atos SE (AEXAY) on Behalf of Investors
- Gary S. Monroe, C.D. Accelerates Promising New Treatments For Cocaine And Methamphetamine Addicts
- Pennsylvania: Gov Wolf Applauds President on Gun Safety Orders, Calls on General Assembly to Take Action
- Survey reveals a third of U.S. homeowners experienced a utility interruption during the COVID-19 pandemic as 19.5 million Americans plan digging projects this spring
- ExpressCells Completes Series A2 Financing
If you purchased or otherwise acquired bluebird securities during the Class Period, you may move the Court no later than April 13, 2021 to ask the Court to appoint you as lead plaintiff if you meet certain legal requirements. To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action. If you wish to learn more about this class action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020, by telephone at (215) 638-4847, toll-free at (888) 638-4847, or by email to howardsmith@howardsmithlaw.com, or visit our website at www.howardsmithlaw.com.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Filed Under: Business
0 Comments
Latest on The PennZone
- Julia Hair Spring Sale Up To 46% Off With Buy Now Pay Later
- CB Insights Again Names AI.Reverie a Top 100 AI Startup
- PQ Group Holdings to Host Virtual Investor Conference on Thursday, April 8, 2021 at 10:00 ET; Focus will be Target PQ, a High Growth Pure-Play Catalyst and Services Company
- Ismail Sirdah's Helpful Tips For Selling Event Ticket Online
- INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Ubiquiti Inc. (UI) on Behalf of Investors
- Sandline Global Broadens Commitment to Data & Analytics: Adam Poeppelmeier Joins as Director of Business Intelligence
- The Savory Grape Launches New Online Shopping And Delivery Experience
- Covid-19 Quarantine Spawns 18 "Pregnancy After 40" Birth Announcements From Group Members in a Single Week
- Waypoint Orthopedics Today Announced the Appointment of Jeffrey F. O'Donnell, Jr. as President
- Spencer, Okla., Selects Inframark for Its Water, Wastewater Operations
- INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Ebang International Holdings, Inc. (EBON) on Behalf of Investors
- Pennsylvania: Gov. Wolf Recognizes Grocery Store Workers, Now Vaccine Eligible, for Heroic Work
- Massage Therapy Center in Los Angeles is Putting a Spring Back In Your Step
- Multi-platinum singer Linda Varg and Audilus to join forces
- COE Distributing Names New President, Restructures for Long-term Growth
- Social Security The Great Ponzi Scheme: "If This Book Doesn't Raise Your Blood Pressure, You'd Better Check For A Pulse!"
- National Minority Health Association Launches PSA to Increase Vaccine Confidence in Minority Communities
- Comcast Business and Versa Networks Drive Further SD-WAN Innovation on ActiveCore℠ Platform
- DeRonja Real Estate Welcomes Mackenzie Seiter
- TVS Main Street Network Returns Petticoat Junction to Tuesday Nights on WatchYour.TV Platform